News

Generic Carvedilol Receives Green Light From FDA


 

The first generic formulations of the beta-blocker carvedilol (Coreg) have been approvedby the Food and Drug Administration for treating hypertension, mild to severe chronic heart failure, and left ventricular dysfunction following a myocardial infarction in clinically stable patients.

Available in four strengths—3.125 mg, 6.25 mg, 12.5 mg, and 25 mg—the tablets are made by these companies: Actavis Elizabeth LLC, Apotex Inc., Aurobindo Pharma Ltd., Caraco Pharmaceutical Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Ltd., Sandoz Inc., Taro Pharmaceutical Industries Ltd., TEVA Pharmaceuticals USA, Watson Laboratories Inc., and Zydus Pharmaceuticals (USA) Inc.

Recommended Reading

Metabolic Syndrome Tied to Mortality After CABG
MDedge Family Medicine
Benefits of Low-Dose Aspirin Alone Offset Costs
MDedge Family Medicine
Cardiac Catheterization A Must in PAH Diagnosis
MDedge Family Medicine
Benefit of Revascularization in Women Questioned
MDedge Family Medicine
Silent Heart Ischemia Appears Reversible in Type 2 Diabetes
MDedge Family Medicine
Normal Angiogram No Reason to Let Guard Down
MDedge Family Medicine
Thrombolysis For DVT Ups Risk of Death
MDedge Family Medicine
Bosentan Slows Progression of Class II PAH
MDedge Family Medicine
High Blood Pressure Rates Rise in Children, Teens
MDedge Family Medicine
Adiposity Labeled a Risk Factor for Ischemic Stroke
MDedge Family Medicine